NADPH dehydrogenase (quinone)

(redirected from DT-diaphorase)

NADPH de·hy·dro·gen·ase (quin·one)

a flavoprotein that oxidizes NADH or NADPH to NAD+ or NADP+ with quinones (for example, menadione) as hydrogen acceptors.
References in periodicals archive ?
lung, kidney and forestomach, for the activities of GSH S-transferase (GST), DT-diaphorase (DTD), superoxide dismutase (SOD) and catalase.
The resulting supernatant (cytosolic fraction) was used for assaying total cytosolic GSH S-transferase (GST), DT-diaphorase (DTD), Lactate dehydrogenase (LDH) and antioxidant enzymes.
Apaziquone is a novel anticancer drug that is activated, to become a cytotoxic alkylating agent, by bio-reductive enzymes, such as DT-diaphorase, that are over-expressed in bladder cancer cells.
RH1 is a small molecule chemotherapeutic agent that is bioactivated by the enzyme DT-diaphorase (DTD), which is over-expressed in many tumors, including lung, colon, breast and liver tumors.
The hepatic glutathione S-transferase and DT-diaphorase specific activities were elevated above basal level by basil leaf treatment (from p < 0.
RH1 is a novel small molecule chemotherapeutic agent that the Company believes is bioactivated by the enzyme DT-diaphorase, or DTD, which the Company believes is over-expressed in many tumors, including lung, colon, breast and liver tumors.
RH1 is a novel small molecule chemotherapeutic agent that is bioactivated by the enzyme DT-diaphorase, or DTD, which is over-expressed in many tumors, including lung, colon, breast and liver tumors.
5] R), glutathione S-transferase (GST), DT-diaphorase (DTD), glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD) and catalase (CAT) showed a significant increase in the liver at both dose levels of extract.
RH1 is a novel small molecule chemotherapeutic agent that we believe is bioactivated by the enzyme DT-diaphorase, or DTD, which we believe is over-expressed in many tumors, including lung, colon, breast and liver tumors.
RH1 is a novel, small molecule chemotherapeutic agent that is bioactivated by the enzyme DT-diaphorase, or DTD, which is over-expressed in many tumors, including lung, colon, breast and liver tumors.
The Company's other product candidates are: PDX (pralatrexate), a small molecule chemotherapeutic agent (DHFR inhibitor) currently under investigation in patients with non-small cell lung cancer and Non-Hodgkin's lymphoma; and RH1, a small molecule chemotherapeutic agent bioactivated by the enzyme DT-diaphorase currently under evaluation in patients with advanced solid tumors.
The Company's other product candidates are: PDX (pralatrexate), a small molecule chemotherapeutic agent (DHFR inhibitor) currently under investigation as both a single agent and in combination therapy regimens in patients with non-small cell lung cancer and Non-Hodgkin's lymphoma; and RH1, a small molecule chemotherapeutic agent bioactivated by the enzyme DT-diaphorase currently under evaluation in patients with advanced solid tumors.